Immunogenicity Assay Assessment

Newly developed biologics, including biosimilars, bispecifics, and antibody drug conjugates, have unique features and require a specific skill set. To continue pushing safe and efficacious products to patients, researchers must adapt. At the Ninth Annual Strategies for Immunogenicity Assay Assessment, industry experts will deliver case studies and critical insight into development, optimization, and validation of immunogenicity assays. This event will address proactive strategies for managing off-target toxicity and mitigating risks from concept to product.


Cell-Based Assays for the Detection of Neutralizing Antibodies against BiTe Molecules and ADCC-Based Therapeutic Monoclonal Antibodies

Yao Zhuang, Ph.D., Principal Scientist, PKDM Bioanalytical Sciences, Amgen

A Neutralizing Antibody Assay Based on a Reporter of Antibody-Dependent Cell-Mediated Cytotoxicity

Yuling Wu, Ph.D., Principal Scientist, Clinical Pharmacology & DMPK, Translational Sciences, MedImmune

Optimizing Reporter-Gene Assays for the Quantification of Neutralizing Anti-Drug Antibodies

Michael Tovey, Ph.D., INSERM Director of Research, Laboratory of Biotechnology & Applied Pharmacology, Ecole Normale Supérieure de Cachan


Case Studies and Methods for Limiting Target Interference in Anti-Drug Antibody Assays

Jim McNally, Ph.D., Associate Director, QPD Program Representative and Immunogenicity Expert at EMD Serono, Inc.

Optimal ADA Assay Formats for Different Drug Modalities

Shalini Gupta, Ph.D., Director, Clinical Immunology, Amgen, Inc.

PandA: A Novel Method Effective at Reducing or Eliminating the Drug and Target Interferences In Immunogenicity Assays

Jad Zoghbi, Senior Scientist, Sanofi (Genzyme)

Method to Improve the Recovery of pH Labile Anti-Drug Antibodies during Acid Dissociation and Extraction

Weifeng Xu, Ph.D., Senior Research Investigator, BAS-Biologics, BMS


Immunogenicity Assessment of Multi-Specific Antibodies

Laura I. Salazar-Fontana, Strategic Advisor for Immunology and Biomarkers, Sanofi R&D

Bioanalytical Strategy for a Bispecific Antibody in Cancer Immunotherapy

Kyra J. Cowan, Ph.D., Scientist, Genentech/Roche

For more details on the conference, please contact:

For partnering and sponsorship information, please contact:

Samantha Drinkwater
Conference Producer
T: 781-972-5461

Jason Gerardi
(Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452

Carol Dinerstein
(Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471